Elekta AB ser. B (EKTAb)

Stockholm
Currency in SEK
63.40
+0.45(+0.71%)
Closed
EKTAb Scorecard
Full Analysis
Valuation implies a strong free cash flow yield
Fair Value
Day's Range
63.1063.90
52 wk Range
58.2088.85
Key Statistics
Edit
Prev. Close
62.95
Open
63.2
Day's Range
63.1-63.9
52 wk Range
58.2-88.85
Volume
655.11K
Average Volume (3m)
1.2M
1-Year Change
-16.8%
Book Value / Share
27.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EKTAb Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
72.54
Upside
+14.41%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Elekta AB ser. B Company Profile

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Employees
4580
Market
Sweden

Compare EKTAb to Peers and Sector

Metrics to compare
EKTAb
Peers
Sector
Relationship
P/E Ratio
24.2x28.7x−0.6x
PEG Ratio
−0.950.710.00
Price/Book
2.3x2.2x2.6x
Price / LTM Sales
1.4x3.4x3.1x
Upside (Analyst Target)
4.1%14.2%53.6%
Fair Value Upside
Unlock8.8%8.0%Unlock

Analyst Ratings

3 Buy
4 Hold
7 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 72.54

(+14.41% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.62
Dividend Yield
3.79%
Industry Median 1.08%
Annualized payout
2.4000
Paid unevenly
5-Years Growth
+5.92%
Growth Streak

Earnings

Latest Release
Nov 27, 2024
EPS / Forecast
0.63 / 0.82
Revenue / Forecast
4.34B / 4.51B
EPS Revisions
Last 90 days

People Also Watch

690.10
LVMH
-0.78%
5,014.0
RKT
+2.56%
426.80
BTRW
+0.61%
386.30
RTO
+0.63%
7,270.0
SPX
+4.98%

FAQ

What Is the Elekta B (EKTAb) Stock Price Today?

The Elekta B stock price today is 63.40

What Stock Exchange Does Elekta B Trade On?

Elekta B is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for Elekta B?

The stock symbol for Elekta B is "EKTAb."

Does Elekta B Pay Dividends? What’s The Current Dividend Yield?

The Elekta AB ser. B dividend yield is 3.79%.

What Is the Elekta B Market Cap?

As of today, Elekta B market cap is 24.22B.

What is Elekta B Earnings Per Share?

The Elekta B EPS is 2.62.

What Is the Next Elekta B Earnings Date?

Elekta B will release its next earnings report on Feb 20, 2025.

From a Technical Analysis Perspective, Is EKTAb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.